Life Science Investing Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 12 December
Life Science Investing Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates 06 November
Life Science Investing Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November 03 November
